Opening a New GATAway for Treating KRAS-Driven Lung Tumors

详细信息	查看全文 | 推荐本文 |

• 作者：Mariano Barbacid¹ ; ^{mbarbacid@cnio.es}
• 刊名：Cancer Cell
• 出版年：2012
• 期刊代码：43_15356108
• 类别：med
• 出版时间：15 May, 2012
• 卷：21
• 期：5
• 页码：598-600
• 文件大小：194 K

摘要

In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of聽GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations unveil new armamentaria to fight this deadly disease.